Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 401

  • Quoted phrase not found.
1.

A study paradigm integrating prospective epidemiologic cohorts and electronic health records to identify disease biomarkers.

Mosley JD, Feng Q, Wells QS, Van Driest SL, Shaffer CM, Edwards TL, Bastarache L, Wei WQ, Davis LK, McCarty CA, Thompson W, Chute CG, Jarvik GP, Gordon AS, Palmer MR, Crosslin DR, Larson EB, Carrell DS, Kullo IJ, Pacheco JA, Peissig PL, Brilliant MH, Linneman JG, Namjou B, Williams MS, Ritchie MD, Borthwick KM, Verma SS, Karnes JH, Weiss ST, Wang TJ, Stein CM, Denny JC, Roden DM.

Nat Commun. 2018 Aug 30;9(1):3522. doi: 10.1038/s41467-018-05624-4.

2.

Methylglyoxal-derived posttranslational arginine modifications are abundant histone marks.

Galligan JJ, Wepy JA, Streeter MD, Kingsley PJ, Mitchener MM, Wauchope OR, Beavers WN, Rose KL, Wang T, Spiegel DA, Marnett LJ.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):9228-9233. doi: 10.1073/pnas.1802901115. Epub 2018 Aug 27.

3.

Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).

Bergmeijer TO, Reny JL, Pakyz RE, Gong L, Lewis JP, Kim EY, Aradi D, Fernandez-Cadenas I, Horenstein RB, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Déry JP, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Simon T, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Hulot JS, Mitchell BD, Schwab M, Ritchie MD, Klein TE, Shuldiner AR; ICPC Investigators.

Am Heart J. 2018 Apr;198:152-159. doi: 10.1016/j.ahj.2017.12.010. Epub 2017 Dec 17.

PMID:
29653637
4.

PharmCAT: A Pharmacogenomics Clinical Annotation Tool.

Klein TE, Ritchie MD.

Clin Pharmacol Ther. 2018 Jul;104(1):19-22. doi: 10.1002/cpt.928. Epub 2017 Dec 1.

5.

PLATO software provides analytic framework for investigating complexity beyond genome-wide association studies.

Hall MA, Wallace J, Lucas A, Kim D, Basile AO, Verma SS, McCarty CA, Brilliant MH, Peissig PL, Kitchner TE, Verma A, Pendergrass SA, Dudek SM, Moore JH, Ritchie MD.

Nat Commun. 2017 Oct 27;8(1):1167. doi: 10.1038/s41467-017-00802-2.

6.

Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT).

Karnes JH, Shaffer CM, Cronin R, Bastarache L, Gaudieri S, James I, Pavlos R, Steiner HE, Mosley JD, Mallal S, Denny JC, Phillips EJ, Roden DM.

Pharmacotherapy. 2017 Sep;37(9):1164-1171. doi: 10.1002/phar.1983. Epub 2017 Sep 4.

7.

Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants.

Karnes JH, Bastarache L, Shaffer CM, Gaudieri S, Xu Y, Glazer AM, Mosley JD, Zhao S, Raychaudhuri S, Mallal S, Ye Z, Mayer JG, Brilliant MH, Hebbring SJ, Roden DM, Phillips EJ, Denny JC.

Sci Transl Med. 2017 May 10;9(389). pii: eaai8708. doi: 10.1126/scitranslmed.aai8708.

8.

Azithromycin Causes a Novel Proarrhythmic Syndrome.

Yang Z, Prinsen JK, Bersell KR, Shen W, Yermalitskaya L, Sidorova T, Luis PB, Hall L, Zhang W, Du L, Milne G, Tucker P, George AL Jr, Campbell CM, Pickett RA, Shaffer CM, Chopra N, Yang T, Knollmann BC, Roden DM, Murray KT.

Circ Arrhythm Electrophysiol. 2017 Apr;10(4). pii: e003560. doi: 10.1161/CIRCEP.115.003560.

9.

Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.

Strauss DG, Vicente J, Johannesen L, Blinova K, Mason JW, Weeke P, Behr ER, Roden DM, Woosley R, Kosova G, Rosenberg MA, Newton-Cheh C.

Circulation. 2017 Apr 4;135(14):1300-1310. doi: 10.1161/CIRCULATIONAHA.116.023980. Epub 2017 Feb 17.

10.

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.

Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JR, Weitzel KW, Cooper-DeHoff RM, Cavallari LH, O'Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, Freimuth RR; Pharmacogenomics Research Network Translational Pharmacogenetics Program.

Clin Pharmacol Ther. 2017 Sep;102(3):502-510. doi: 10.1002/cpt.630. Epub 2017 Jun 9.

11.

STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION.

Wiley LK, Vanhouten JP, Samuels DC, Aldrich MC, Roden DM, Peterson JF, Denny JC.

Pac Symp Biocomput. 2017;22:545-556. doi: 10.1142/9789813207813_0050.

12.

Gene-gene Interaction Analyses for Atrial Fibrillation.

Lin H, Mueller-Nurasyid M, Smith AV, Arking DE, Barnard J, Bartz TM, Lunetta KL, Lohman K, Kleber ME, Lubitz SA, Geelhoed B, Trompet S, Niemeijer MN, Kacprowski T, Chasman DI, Klarin D, Sinner MF, Waldenberger M, Meitinger T, Harris TB, Launer LJ, Soliman EZ, Chen LY, Smith JD, Van Wagoner DR, Rotter JI, Psaty BM, Xie Z, Hendricks AE, Ding J, Delgado GE, Verweij N, van der Harst P, Macfarlane PW, Ford I, Hofman A, Uitterlinden A, Heeringa J, Franco OH, Kors JA, Weiss S, Völzke H, Rose LM, Natarajan P, Kathiresan S, Kääb S, Gudnason V, Alonso A, Chung MK, Heckbert SR, Benjamin EJ, Liu Y, März W, Rienstra M, Jukema JW, Stricker BH, Dörr M, Albert CM, Ellinor PT.

Sci Rep. 2016 Nov 8;6:35371. doi: 10.1038/srep35371.

13.

Evaluation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records.

Kolek MJ, Graves AJ, Xu M, Bian A, Teixeira PL, Shoemaker MB, Parvez B, Xu H, Heckbert SR, Ellinor PT, Benjamin EJ, Alonso A, Denny JC, Moons KG, Shintani AK, Harrell FE Jr, Roden DM, Darbar D.

JAMA Cardiol. 2016 Dec 1;1(9):1007-1013. doi: 10.1001/jamacardio.2016.3366.

14.

Population-specific single-nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans.

Daneshjou R, Cavallari LH, Weeke PE, Karczewski KJ, Drozda K, Perera MA, Johnson JA, Klein TE, Bustamante CD, Roden DM, Shaffer C, Denny JC, Zehnder JL, Altman RB.

Mol Genet Genomic Med. 2016 Jun 21;4(5):513-20. doi: 10.1002/mgg3.226. eCollection 2016 Sep.

15.

Variants in the SCN5A Promoter Associated With Various Arrhythmia Phenotypes.

Yagihara N, Watanabe H, Barnett P, Duboscq-Bidot L, Thomas AC, Yang P, Ohno S, Hasegawa K, Kuwano R, Chatel S, Redon R, Schott JJ, Probst V, Koopmann TT, Bezzina CR, Wilde AA, Nakano Y, Aiba T, Miyamoto Y, Kamakura S, Darbar D, Donahue BS, Shigemizu D, Tanaka T, Tsunoda T, Suda M, Sato A, Minamino T, Endo N, Shimizu W, Horie M, Roden DM, Makita N.

J Am Heart Assoc. 2016 Sep 13;5(9). pii: e003644. doi: 10.1161/JAHA.116.003644.

16.

A biologically informed method for detecting rare variant associations.

Moore CCB, Basile AO, Wallace JR, Frase AT, Ritchie MD.

BioData Min. 2016 Aug 30;9(1):27. doi: 10.1186/s13040-016-0107-3. eCollection 2016.

18.

Partial Duplication and Poly(A) Insertion in KCNQ1 Not Detected by Next-Generation Sequencing in Jervell and Lange-Nielsen Syndrome.

Bersell K, Montgomery JA, Kanagasundram AN, Campbell CM, Chung WK, Macaya D, Konecki D, Venter E, Shoemaker MB, Roden DM.

Circ Arrhythm Electrophysiol. 2016 Jun;9(6). pii: e004081. doi: 10.1161/CIRCEP.116.004081. No abstract available.

19.

Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients.

McCauley M, Vallabhajosyula S, Darbar D.

Card Electrophysiol Clin. 2016 Jun;8(2):481-93. doi: 10.1016/j.ccep.2016.02.009. Epub 2016 Mar 22. Review.

20.

Pharmacogenetics of Potassium Channel Blockers.

Roden DM.

Card Electrophysiol Clin. 2016 Jun;8(2):385-93. doi: 10.1016/j.ccep.2016.02.003. Review.

Supplemental Content

Loading ...
Support Center